RecruitingPhase 2NCT07089043

A Study in Subjects With Neurogenic Orthostatic Hypotension

A Single-Blind Dose-Ranging Study in Subjects With Neurogenic Orthostatic Hypotension to Evaluate the Effect of CST-3056 on Symptoms and Signs of Orthostatic Hypotension


Sponsor

CuraSen Therapeutics, Inc.

Enrollment

12 participants

Start Date

Sep 12, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a study to evaluate the effects of CST-3056 on orthostatic symptoms and signs in subjects with neurogenic orthostatic hypotension (nOH).


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CST-3056 and a drug called Placebo for people with neurogenic orthostatic hypotension. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCST-3056

Administered as an oral solution

DRUGPlacebo

Administered as an oral solution


Locations(5)

CuraSen Investigational Site

Scottsdale, Arizona, United States

CuraSen Investigational Site

Farmington Hills, Michigan, United States

CuraSen Investigational Site

Eatontown, New Jersey, United States

CuraSen Investigational Site

New York, New York, United States

CuraSen Investigational Site

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07089043


Related Trials